tbuckley/cabot-search huggingface dataset:
The incremental yield of endoscopic ultrasound over endobronchial ultrasound and CT for detection of extrathoracic metastases in lung cancer
Authors: J Conway, G Silvestri, C Reed, J Romagnuolo, R Hawes, J Ravenel, B Hoffman
Journal: Endoscopy (2006)

Background: Endoscopic Ultrasound (EUS) with fine needle aspiration (FNA), is an established modality for staging of non-small cell lung cancer. EUS-FNA can also detect suspected extrathoracic metastases in the celiac area, left adrenal, and liver. Endobronchial US (EBUS) has the ability of reviewing thoracic stations not accessible by EUS but cannot review extrathoracic areas.
P2-19-04: Changes in Adjuvant Treatment of Early Breast Cancer in Italy between 2000 and 2008. The NEMESI Study Versus the NORA Study.
Authors: G Mustacchi, ME Cazzaniga, P Pronzato, M Clavarezza, Mastro L Del, M Venturini, D Amadori, P Bidoli, C Boni, M Caruso, F Riccardi, D Dondi
Journal: Cancer Research (2011)

Abstract Background: In the early 2000s, we identified treatment patterns of early breast cancer (EBC) in Italy (NORA study). To ascertain whether attitudes have changed, we conducted a similar study in 2008. Patients and methods: In this retrospective study (NEMESI), we recorded the clinical, tumour and treatment characteristics of 1.894 EBC patients in 63 Italian oncological centres in 2008, and compared the results with those of NORA, on 3.515 patients in 70 same/similar Italian institutions, in 2000–2003. Tumor stage, surgery and endocrine-responsiveness are not comparable because of different recruitment protocols, patients charactheristics and adjuvant treatment strategies are perfectly comparable as a reliable picture of adjuvant strategies in Italy. Results: There was no difference in age class distribution, menopausal status, ECOG performance status, tumor grade, ki67 and estrogen receptors content. HER2 status was simila but determined in 98% of cases in NEMESI vs 46.2% in NORA. The overall use of endocrine treatment (HT) increased from 80.3% in NORA to 83.5% in NEMESI (p = 0.005); the overall use of chemotherapy (CHT) decreased from 68.4% to 57.8% (p = 0.00001). HT alone increased from 31.6% to 42.2% (P = 0.00001) and CHT alone decreased from 18.8% to 16.2% (p = 0.017). The use of both treatments decreased from 49.2% to 41.6% (p = 0.00001). Trastuzumab was never given in NORA and in 15% of cases in NEMESI (85% of all HER2 positive cases). The choice for HT was tamoxifen for 5 years in 32.5% of cases in NEMESI and 86.6% in NORA (p = 0.000001), and aromatase inhibitors for 5 years in 55.2% vs 13.3% of cases, respectively (P = 0.000001). The “switch” from tamoxifen 2–3 years to aromatase inhibitors 2–3 years was planned in 10.1% of cases in NEMESI and actually done in 12.9% of cases in NORA (p = 0.001). The overall use of LHRH analogues was significantly higher in NEMESI vs NORA (26.7% vs 3.0%, p = 0.00001). CMF-like regimens decreased from 37.0% in NORA to 9.1% (p = 0.000001). Anthracycline-containing regimens decreased from 52.1% in NORA to 48.8% in NEMESI; p = 0.0001) in favour of of regimens containing anthracyclines and taxanes, either in combination or sequential (0.9% in NORA vs 38.4% in NEMESIS, p = 0.000001). The use of taxanes alone regimens remained low (3.5% vs 3.7%, ns). The overall use of anthracyclines and taxanes increased from 53.0% to 87.5% and from 4.3% to 42.1%, respectively (both p =0.00001). Conclusions: EBC treatment has changed significantly in 6 years. Adjuvant strategies are significantly different, with a great increase of aromatase inhibitors and LHRH analogues associated with tamoxifen; anthra-taxane combinations have also significantly increased. Financial Support by Sanofi Aventis Italy Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-19-04.
Albert J Jovell
Authors: A. G. Rada
Journal: BMJ (2014)

“Nothing teaches you more than knowing you have little time left,” Albert J Jovell said to a newspaper in 2012. He himself had been a committed student since he was diagnosed with a rare neuroendocrine cancer of the thymus in 2001. Over the years he experienced repeated relapses, until the disease ended his life in 2013. As well as being a doctor, therefore, Jovell was also a patient, and he dedicated many years to defending the rights of patients as president of the Spanish Patients’ Forum. The forum is known as “the patient’s voice in democracy”, and represents most of Spain’s patients’ organisations. Jovell was also director of the Patients’ University at the School of Medicine and Surgery of the Autonomous University of Barcelona. One of his achievements was the “political agenda” of the Spanish Patients’ Forum, which established specific policy actions to improve patients’ quality of life and participation in political decisions. Jovell himself wanted to call it “the political and social agenda.” He would have been happy to know that recent protests forced the end of the largest plan to date to privatise Spain’s healthcare system. “For Spaniards, the right to healthcare is associated with the respect for human dignity, something independent from people, social class, and facts,” he wrote in a BMJ blog. Jovell graduated in medicine from the University of Barcelona (UB) in 1986, and in sociology and political sciences from the Autonomous University of Barcelona in 1990. He held a doctorate in sociology from the UB, and a doctorate in public health and an MPH from Harvard; furthermore he was director of the Global Institute of Public Health and Health Policy of the International University of Catalunya. His numerous articles mostly focused on the need to humanise medicine. “He thought that the survival of cancer patients should be measured in units of happiness,” says Sergio Minue, a GP and professor at the Andalusian School of Public Health. ForMinue, Jovell’s illness and ultimate death were “a chronicle of a death foretold: not only did he not deny his illness, but he showed it, almost proudly, as a way to support many sick, anonymous people who carry their suffering almost in secret.” Jovell was generous with his time and always available to answer health journalists’ questions. On those occasions when he was too ill he would find someone else to speak on his behalf. One of those persons was the sociologist Giovana Gabrielle who said, “Collaborating with him meant to raise the voice of the patient to the highest authorities at a national, regional, European and international level. [...] He taught me to hate bureaucracy, to work with independent criteria, not to trust appearances, to value the time that we give, to cherish ourselves depending on the extent of our merits, not to waste or give away our time in vain, rarely to say ‘no,’ and to be forever grateful.” Jovell is survived by his wife, Maria Dolores Navarro Rubio, a specialist in preventive medicine and public health; and their two sons.
Abstract 1547: Acquisition of resistance to the β1 integrin antagonist HYD1 correlates with decreased α4, α6, αV and β1 integrin expression and decreased adhesion to fibronectin, VCAM-1 and vitronectin
Authors: Michael Emmons, Rajesh Nair, Mark McLaughlin, Steven Eschrich, Anne Cress, Lori Hazlehurst
Journal: Cancer Research (2010)

Abstract Our laboratory recently reported that the D amino acid-containing β1 integrin inhibitory peptide HYD1 causes caspase independent cell death in multiple myeloma (MM) cell lines as a single agent in vitro and in vivo (Nair et al Molecular Cancer Therapeutics, 2009). Exposure of MM cells to HYD1 induces autophagy, but autophagy was shown to contribute to survival following HYD1 treatment. HYD1 treatment induces cell death in MM cell lines indicative of necrosis. These characteristics included: (a) an increase in the levels of reactive oxygen species (ROS), (b) ATP depletion and (c) loss of mitochondrial membrane potential. To further characterize the mechanism of HYD1 induced cell death an isogenic drug resistant variant was developed. This variant, referred to as H929-60, was developed by chronically exposing parental H929 cells to increasing doses of HYD1. Acquired resistance correlated with decreased HYD1 induced TO-PRO-3 positivity, decreased levels of ROS, reduced ATP depletion and reduced mmp loss compared to the H929 cell line. Additionally, the drug resistant variant H929-60 cells displayed decreased cell surface binding of FAM-HYD1 compared to H929 cells. These data indicate that decreased expression of the binding target(s) of HYD1 may contribute to drug resistance. Gene expression profiling (GEP) was used as an unbiased approach to identify changes in gene expression that may contribute to HYD1 resistance. Differentially expressed genes were mined in silico using the pathway analysis programs Ingenuity and GeneGo. The integrin signaling hub showed substantial changes in gene expression in the drug resistant variant compared to the parental cell line. Specifically, α4, α6, αV and β1 integrins were all down regulated along with the integrin associated protein CD47 in the HYD1 resistant cell line. These changes were consistent with decreased protein expression of integrins on the cell membrane and decreased functional adhesion to fibronectin, vitronectin and VCAM-1. Reducing the expression of α4 integrin using shRNA in the parental H929 cell line conferred partial resistance to HYD1 induced cell death. Together our data show that the acquisition of resistance to HYD1 correlated with decreased integrin expression and functional binding to extracellular matrixes. Future studies aim to determine whether a decrease in α6, αV and β1 integrins on the cell surface contributes to HYD1 resistance. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1547.
AB0477 Comparative Analysis of the Faults, Complications, Follow up in Patients with Wide Spectrum for Rheumatic Diseases Attached to Total Hip Replacement
Authors: V.P. Pavlov, S.A. Makarov
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> The feasible of the total hip replacement (THR) in the wide spectrum rheumatic diseases with hip involvements, analysis of the faults, complications, preliminary follow up. <h3>Methods</h3> The are 1069 patients, 773 women and 296 men (3,6:1), mean age 49,6 y. (16-83 y), 323 – rheumatoid arthritis (RA), 124 – juvenile rheumatoid arthritis (JRA), 80- ankylosing spondylitis (AS),79 – systemic lupus erythematosis (SLE), 11- systemic sclerodermia (SSD), 18- psoriatic arthropathy (PsA), 353 – osteoarthritis (OA), 21 – syndromes and methabolic diseases, 40 – spontaneous and traumatic cervical hip fractures in RA and senile patients. In total - 1201 THR including 135 double procedures. <h3>Results</h3> Complications: mortality – 4 patients (0,37%) - from acute adrenal insufficiency-1, myocardium infarction-2, purulent bronchitis exacerbation-1.Thromboembolism of pulmonary artery branch-1 patient {0,083%), phlebothrombosis – 4 patients (0,37%) with satisfactory outcome after intensive anticoagulant therapy. Aseptic implant loosening - in one JRA patient over 9 post-up years with satisfactory result after revision surgery. Periprosthetic infection- in 9 cases (0, 74%) among them 3- early and 6 - late, from those 7- in RA, 1-SLE, 1–OA. The treatment: revision9s debridement and intensive salvage therapy with implants preserved in one OA and removed in RA patients. 5 RA patients are need in repeated revision surgery. One RA patient died from diabetes. Preliminary follow up had valued before and 2-12 y (mean 4,6 y.) after THR by HHS in RA, JRA, SLE, AS, OA, PsA patients (n-173) as 32,3±3,8/81,7±8,6 points. Functional status and life quality had valued by index HAQ and enquire EQ-5D before and after THA – in RA, AS, OA patients (n-90) 1,81±0,2/0,88±0,2 and in RA, JRA, AS,OA patients (n-112) 0,06±0,06/0,65±0,07 correspondently. <h3>Conclusions</h3> THR in patients of wide spectrum rheumatic diseases was accompanied by modest risk of peri- and postoperative complications. Preliminary follow up testified to essential improvement of operative joints, functional status and life quality in rheumatic patients. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1672
ASSOCIATION OF FIVE-YEAR CHANGE IN N-TERMINAL FRAGMENT OF THE PROHORMONE BRAIN-TYPE NATRIURETIC PEPTIDE WITH CHANGE IN LEFT VENTRICULAR MASS AND INCIDENT HYPERTROPHY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: THE HEART AND SOUL STUDY
Authors: Mitchell Psotka, Nelson Schiller, Mary Whooley, Rakesh Mishra
Journal: Journal of the American College of Cardiology (2016)
George Izatt Hendry
Authors: M. W. Hendry
Journal: BMJ (2014)

George Izatt Hendry was born and educated in Dunfermline. He attended Dunfermline High School, where he became head boy and captain of the cricket team. His medical training at Edinburgh University was followed by house jobs in Dunfermline hospitals and Western General Hospital, Edinburgh. He became trainee to R C Wallace, who had graduated in Edinburgh in 1910. Initially appointed assistant, he took over the dispensing …
Tc-99m Tetrofosmin Lymph Node Uptake in Myocardial Perfusion Imaging
Authors: A. BESTETTI, R. POSTERLI, R. CHIAPPARINO, L. PEDRAZZINI, G. L. TAROLO
Journal: Clinical Nuclear Medicine (1996)

A 60-year-old man, who was believed to have angina, underwent Tc-99m Tetrofosmin SPECT imaging during rest myocardial perfusion study, which showed an abnormal uptake with visualization of left axillary lymph nodes. Further investigation with Tc-99m nanocolloid lymphoscintigraphy and left axillary echography did not show neoplastic axillary lymph node enlargement. Abnormal lymph node uptake was probably due to lymphatic drainage after partial extravasation of radiopharmaceutical during left arm intravenous injection.
PD-1 and FOXP3 Predicting the Response to Neoadjuvant-Chemotherapy_(NAC) of Breast Cancer
Authors: T. Sawada, S. Akashi, Y. Hirota, K. Enokido, T. Kuwayama, R. Yoshida, H. Oyama, T. Takamaru, M. Ikeda, S. Nakamura
Journal: Annals of Oncology (2013)
Abstract 2988: Exploring the association between immune-related genetic variations and virally mediated head and neck cancer
Authors: Chaya Levovitz, Marshall Posner, James McKay, Paolo Boffetta, Andrew Sikora
Journal: Cancer Research (2012)

Abstract OBJECTIVES: Human papilloma virus (HPV)-related cancer of the oropharynx (tonsil and tongue base) makes up an increasing proportion of head and neck cancers. This raises the possibility that the host immune response may modulate susceptibility to HPV-related head and neck cancer. The overall goal of this project is to identify candidate immune-related genes associated with an increased risk of developing virally-mediated head and neck squamous cell carcinoma (HNSCC). STUDY DESIGN: Data from a two-phased Genome Wide Association Study (GWAS) performed by the International Head and Neck Cancer Epidemiology Consortium (INHANCE) was evaluated for associations between genetic variants in candidate immune related genes and the risk of developing HNSCC. METHODS: We analyzed the GWAS dataset using a hypothesis-driven multi-candidate gene approach which incorporates improved methods for data quality control and candidate gene prioritization. This involved performing an association analysis using multi-variate logistic regression with over 300,000 SNPs. The candidate gene list, including over 900 immune-related genes, was developed using the Gene Ontology (GO) database and prioritized by both the GO priority score and a novel literature based ranking schema. Separate association analyses were performed on all samples and then on samples from patients with oropharyngeal cancer only. RESULTS: After adjusting for multiple testing, 15 of the immune related candidate genes had p values that reached significance in the association study performed on oropharyngeal samples including CBFA2T3, MAPKAPK2, ZAP70, CRTAM, PBX1, MAPK10, CD80, IL10, SOCS5, TGFBR1, EBF1, IGF1R, LYN, ITGAV. Mutations in many of these genes have previously been implicated in cancer risk, viral host-response, or epithelial immunity. CONCLUSIONS: Our analysis suggests that the immune system may modulate risk of developing virally-mediated HNSCC. Genes identified in this study may provide biomarkers for patient or population risk assessments that can potentially be used in implementing behavioral interventions, HPV vaccination, and other preventative strategies. Validation of immune-related genes associated with HNSCC susceptibility may provide clues to pathogenic mechanisms driving the acquisition of virally-related HNSCC. This abstract has been submitted on behalf of ARCAGE and the CE UADT. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2988. doi:1538-7445.AM2012-2988
P86 IMPACT OF GLUTATHIONE PEROXIDASE 4 OVEREXPRESSION ON HEPATOCELLULAR CARCINOMA: AN IN VITRO AND IN VIVO STUDY
Authors: N. Rohr-Udilova, D. Stoiber, E. Bauer, W. Li, M. Seif, H. Hayden, K. Stolze, R. Brigelius-Flohe, R. Eferl, M. Peck-Radosavljevic
Journal: Journal of Hepatology (2014)
VEGF, VEGFR2 and HIF-1α expression in circulating tumor cells (CTCs) of breast cancer patients.
Authors: G Kallergi, S Agelaki, V Gannoukaraki, H Markomanolaki, E Lianidou, D Mavroudis, V Georgoulias
Journal: Cancer Research (2009)

Abstract Abstract #1028 Background: Development of metastasis is associated with the presence of circulating (CTCs) and disseminated (DTCs) tumor cells in peripheral blood and bone marrow of breast cancer patients, respectively. Hypoxia and Vascular Endothelial Growth Factor (VEGF) play an important role in angiogenesis. There is no data published concerning the expression of HIF-1α and VEGF/VEGFR in CTCs. Methods: Double staining immunofluoresent experiments were designed to test the expression of VEGF, VEGFR and HIF-1α in CK (Cytokeratin)-positive CTCs from 34 metastatic breast cancer patients. PBMC cytospins were double stained with a monoclonal pancytokeratin antibody (A45-B/B3) along with each of the following: VEGF, VEGFR2 or HIF-1α polyclonal antibodies, respectively. Results: According to our experiments, CTCs from 62%, 47% and 76% of patients expressed VEGF, VEGFR2 and HIF-1α, respectively. In addition, VEGF, VEGFR2 and HIF-1α were expressed in 73%, 71% and 56% of the total number of examined CTCs, respectively. In 24% of the patients CTCs expressed all the investigated molecules. VEGF expression in CTCs was confirmed by performing RT-PCR with VEGF-specific primers in immunomagnetically-separated epithelial cells. Double and triple staining experiments and confocal microscopic analysis of immunomagnetically-isolated CTCs confirmed that VEGF was co-expressed with HIF-1α and VEGFR. Discussion: VEGF and VEGFR2 colocalization in CTCs indicate the presence of an autocrine loop in these cells. Our results demonstrate VEGF, VEGFR2 and HIF-1α expression in CTCs of patients with metastatic breast cancer and thus constitute the basis for using anti-angiogenic therapy for their elimination. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1028.
Abstract 4556: NOSH-aspirin is a potent inhibitor of colon cancer cell growth: effects of positional isomerism.
Authors: Erin K. Eschbach, Andrew C. MacKessack-Leitch, Federica Vannini, Ravinder Kodela, Mitali Chattopadhyay, Khosrow Kashfi
Journal: Cancer Research (2013)

Abstract Background: We recently reported the synthesis of NOSH-aspirin, a novel hybrid capable of releasing both nitric oxide (NO) and hydrogen sulfide (H2S). In NOSH-aspirin, the two moieties that release NO and H2S are covalently linked at the 1, 2 positions of acetyl salicylic acid, ie ortho-NOSH-aspirin. Here we compared the cell growth inhibitory properties of ortho-NOSH-aspirin to that of the 1,3 (meta-NOSH-aspirin) and the 1,4 (para-NOSH-aspirin) positional isomers. We also incorporated electron donating/withdrawing groups about the bezyl ring in order to evaluate the effect of substitution on stability and biological activity of these novel compounds. Methods: Cell line: HT-29 and HCT 15 human colon adenocarcimoa; Cell growth: MTT; Cell cycle phase distribution: Flow cytometry; Apoptosis: subdiploid (sub-G0/G1) peak in DNA content histograms; Proliferation: PCNA; ROS: measured hydrogen peroxide and super oxide by flow cytometry using DCFDA and DHE dyes. Results: All positional isomers of NOSH-aspirin were potent growth inhibitors of both cell lines. The IC50s for growth inhibition in nM at 24h were, HT-29: ortho-NOSH-ASA (0.04 ± 0.011), meta-NOSH-ASA (0.24 ± 0.11), para-NOSH-ASA (0.46 ± 0.17); significance between the groups were: o vs m P&amp;gt;0.05, o vs p P&amp;lt;0.01, m vs p P&amp;gt;0.05; HCT 15: ortho-NOSH-ASA (0.062 ± 0.006), meta-NOSH-ASA (0.092 ± 0.004), para-NOSH-ASA (0.37 ± 0.04); significance between the groups were: o vs m P&amp;gt;0.05, o vs p P&amp;lt;0.001, m vs p P&amp;lt;0.001. Electron donating/withdrawing groups significantly affected these IC50s. All positional isomers qualitatively had similar effects on proliferation, apoptosis, and caused G0/G1 cell cycle arrest in both colon cancer cell lines. The underlying mechanism for these observations appeared to be mediated through generation of intracellular H2O2 and superoxide anions as pretreatment of cells with N-acetylcysteine, partially blocked these effects. Conclusions: Positional isomerism affects the potency of NOSH-aspirin and offers a platform for drug design. Further, NOSH-aspirin merits further evaluation as an anti-cancer agent. Citation Format: Erin K. Eschbach, Andrew C. MacKessack-Leitch, Federica Vannini, Ravinder Kodela, Mitali Chattopadhyay, Khosrow Kashfi. NOSH-aspirin is a potent inhibitor of colon cancer cell growth: effects of positional isomerism. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4556. doi:10.1158/1538-7445.AM2013-4556
Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects
Authors: MK Arnaout, KM Radomski, DK Srivastava, X Tong, JR Belt, SC Raimondi, FG Behm, VM Santana, WR Crom, J Mirro, RC Ribeiro
Journal: Leukemia (2000)